MedPath

Anodal Transcranial Direct Current Stimulation (tDCS) in the Treatment of Tobacco Addiction

Not Applicable
Completed
Conditions
Addiction
Smoking
Interventions
Procedure: sham tDCS
Procedure: active tDCS
Registration Number
NCT01288183
Lead Sponsor
Hôpital le Vinatier
Brief Summary

The aim of this study is to determine whether a powerful technique of noninvasive brain stimulation, transcranial direct current stimulation (tDCS), could reduce cigarette smoking and constitute a treatment of tobacco addiction.

Detailed Description

Tobacco is estimated to cause more than 5 millions yearly deaths in the developed world. Although most smokers would like to quit, relapse rates remain high. It seems that this relapse is linked with the process of craving, which is a powerful desire to smoke elicited by smoking deprivation or exposure to situations or cues that are associated with smoking. Neuroimaging studies have shown that the dorsolateral prefrontal cortex (DLPFC), and especially the right part, is critically involved in processing the craving of smoking. Increasing the activity of the DLPFC by noninvasive brain stimulation has been demonstrated to be effective in decreasing craving symptoms in cigarette smokers.

The aim of this study is to determine whether a powerful technique of noninvasive brain stimulation, transcranial direct current stimulation (tDCS), could reduce cigarette smoking. tDCS is a painless and safe brain stimulation method capable of modulating cortical excitability. The nature of these modulations depends on stimulation polarity: anodal tDCS is thought to cause neuronal depolarisation and thus enhancing cortical excitability whereas cathodal stimulation is proposed to reduce excitability. The investigators hypothesize that anodal tDCS applied repetitively to the right DLPFC could constitute a treatment of tobacco addiction. Therefore, the investigators will conduct a sham-tDCS-controlled, randomized, double-blind study.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
38
Inclusion Criteria
  • Age from 18 to 55 years old
  • Tobacco consumption from 10 to 25 cigarettes, for at least 1 year
  • Strong tobacco dependence at the Fagerstrom Test (score >= 5)
  • Motivation to quit with a score >=12 at the Motivation to Quit Smoking Scale (Q-MAT)
  • Informed consent
Exclusion Criteria
  • Concomitant Axe I psychiatric disorder according to the Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM IV)
  • Other addictive disorder (DSM IV)
  • No history of smoking cessation drug the previous year
  • Psychotropic treatment
  • Pregnancy or nursing

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
sham tDCSsham tDCSsham transcranial direct current stimulation The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region
active tDCSactive tDCSactive anodal tDCS over the right dorsolateral prefrontal cortex The anode (7 x 5 cm) is placed on the right dorsolateral prefrontal cortex. A large cathode (10 x 10cm) is placed on the left occipital region Intensity of the stimulation: 2 mA Duration of the stimulation: 20 min 10 sessions, 2 per day
Primary Outcome Measures
NameTimeMethod
SmokingBaseline (three days before starting tDCS regimen) to one-month after

Self-reported number of cigarettes smoked each day

Secondary Outcome Measures
NameTimeMethod
Exhaled carbon monoxideBaseline, one-week (after the last tDCS session) and one-month later

measured using a CO monitor (MicroCo, Milford, MA, USA).

CravingFor each of the 10 tDCS sessions: Baseline and 0 hour post-tDCS (immediately after)

measured using a 5-item Likert-type scale questionnaire of smoking urge

fMRI brain reactivity during a smoking cue-reactivity taskBaseline and one-week (after the last tDCS session)

measured using an event-related fMRI paradigm

Trial Locations

Locations (1)

Hopital le Vinatier

🇫🇷

Bron, France

© Copyright 2025. All Rights Reserved by MedPath